This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Lessig, M. K. PubMed PubMed Citation Articles by Lessig, M. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Neuroblastoma Social Bookmarking                         What's this?

The Role of 131I-MIBG in High-Risk Neuroblastoma Treatment

Division of Endocrinology at The Children's Hospital of Philadelphia, Philadelphia, PA, lessigm{at}email.chop.edu

Despite aggressive research and treatment, high-risk neuroblastoma continues to have a devastating mortality rate of more than 40%. Research conducted over the past 2 decades has shown that the radioisotope ¹³¹I-MIBG (metaiodobenzylguanidine) is effective in the treatment of this difficult patient population. The purpose of this article is to review the diagnosis, staging, and conventional treatment of neuroblastoma and to understand the mechanism of action of MIBG and ¹³¹I-MIBG. This article also reviews treatments for high-risk neuroblastoma patients and analyzes recent research studies that used ¹³¹I-MIBG to better define the role of this treatment in high-risk neuroblastoma patients. In addition, this article explores the role of the advanced practice nurse to serve at the forefront in the implementation of a multidisciplinary ¹³¹I-MIBG treatment program.

Key Words: 131I-MIBG • neuroblastoma • treatment • nursing • radiation

Journal of Pediatric Oncology Nursing, Vol. 26, No. 4, 208-216 (2009)
DOI: 10.1177/1043454209340316


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?